| Item Type | Name |
|
Concept
|
Oligopeptides
|
|
Academic Article
|
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
|
|
Academic Article
|
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
|
|
Academic Article
|
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
|
|
Academic Article
|
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
|
|
Academic Article
|
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
|
|
Academic Article
|
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
|
|
Academic Article
|
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.
|
|
Academic Article
|
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
|
|
Academic Article
|
Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
|
|
Academic Article
|
Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma.
|
|
Academic Article
|
Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.
|
|
Academic Article
|
Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.
|
|
Academic Article
|
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
|
|
Academic Article
|
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
|
|
Academic Article
|
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
|
|
Academic Article
|
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
|
|
Academic Article
|
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.
|
|
Academic Article
|
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
|
|
Academic Article
|
Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies.
|
|
Academic Article
|
Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States.
|
|
Academic Article
|
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
|
|
Academic Article
|
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.
|
|
Academic Article
|
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
|
|
Academic Article
|
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
|
|
Academic Article
|
A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia.
|
|
Academic Article
|
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.
|
|
Academic Article
|
Oprozomib in patients with newly diagnosed multiple myeloma.
|
|
Academic Article
|
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
|
|
Academic Article
|
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
|
|
Academic Article
|
Treatments for newly diagnosed multiple myeloma: when endurance is interrupted.
|
|
Academic Article
|
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.
|
|
Academic Article
|
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
|
|
Academic Article
|
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
|
|
Academic Article
|
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
|
|
Academic Article
|
Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies.
|